Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling.

Chng WJ, Kumar S, Vanwier S, Ahmann G, Price-Troska T, Henderson K, Chung TH, Kim S, Mulligan G, Bryant B, Carpten J, Gertz M, Rajkumar SV, Lacy M, Dispenzieri A, Kyle R, Greipp P, Bergsagel PL, Fonseca R.

Cancer Res. 2007 Apr 1;67(7):2982-9.

2.

Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du Myélome.

Decaux O, Lodé L, Magrangeas F, Charbonnel C, Gouraud W, Jézéquel P, Attal M, Harousseau JL, Moreau P, Bataille R, Campion L, Avet-Loiseau H, Minvielle S; Intergroupe Francophone du Myélome.

J Clin Oncol. 2008 Oct 10;26(29):4798-805. doi: 10.1200/JCO.2007.13.8545. Epub 2008 Jun 30.

PMID:
18591550
3.

Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma.

Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, San Miguel JF, Cavenagh JD, Anderson KC.

Br J Haematol. 2007 Jun;137(5):429-35. Epub 2007 Apr 19.

PMID:
17451408
4.

Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial.

Richardson PG, Sonneveld P, Schuster M, Irwin D, Stadtmauer E, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, Miguel JS, Bladé J, Boccadoro M, Cavenagh J, Alsina M, Rajkumar SV, Lacy M, Jakubowiak A, Dalton W, Boral A, Esseltine DL, Schenkein D, Anderson KC.

Blood. 2007 Nov 15;110(10):3557-60. Epub 2007 Aug 9.

5.

Upregulation of translational machinery and distinct genetic subgroups characterise hyperdiploidy in multiple myeloma.

Agnelli L, Fabris S, Bicciato S, Basso D, Baldini L, Morabito F, Verdelli D, Todoerti K, Lambertenghi-Deliliers G, Lombardi L, Neri A.

Br J Haematol. 2007 Feb;136(4):565-73.

PMID:
17367409
6.

Clinical and immunohistochemical features associated with a response to bortezomib in patients with multiple myeloma.

Dawson MA, Opat SS, Taouk Y, Donovan M, Zammit M, Monaghan K, Horvath N, Roberts AW, Prince HM, Hertzberg M, McLean CA, Spencer A.

Clin Cancer Res. 2009 Jan 15;15(2):714-22. doi: 10.1158/1078-0432.CCR-08-1022.

7.

[Efficiency of bortezomib and dexamethasone in relapsed multiple myeloma treatment: retrospective study in consecutive cases].

Khosravi Shahi P, Sabin Domínguez P, Encinas García S, Izarzugaza Perón Y, Pérez Manga G.

An Med Interna. 2008 Feb;25(2):73-7. Spanish.

8.

Expanding role of bortezomib in multiple myeloma: nursing implications.

Colson K, Doss DS, Swift R, Tariman J.

Cancer Nurs. 2008 May-Jun;31(3):239-49. doi: 10.1097/01.NCC.0000305733.80592.8e.

PMID:
18453881
9.

Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study.

Lee SJ, Richardson PG, Sonneveld P, Schuster MW, Irwin D, San Miguel JF, Crawford B, Massaro J, Dhawan R, Gupta S, Anderson KC.

Br J Haematol. 2008 Nov;143(4):511-9. doi: 10.1111/j.1365-2141.2008.07378.x.

PMID:
18986387
10.

Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression.

Mateos MV, Hernández JM, Hernández MT, Gutiérrez NC, Palomera L, Fuertes M, Garcia-Sanchez P, Lahuerta JJ, de la Rubia J, Terol MJ, Sureda A, Bargay J, Ribas P, Alegre A, de Arriba F, Oriol A, Carrera D, García-Laraña J, García-Sanz R, Bladé J, Prósper F, Mateo G, Esseltine DL, van de Velde H, San Miguel JF.

Haematologica. 2008 Apr;93(4):560-5. doi: 10.3324/haematol.12106. Epub 2008 Mar 5.

11.

Weekly treatment with bortezomib for patients with recurrent or refractory multiple myeloma: a phase 2 trial of the Minnie Pearl Cancer Research Network.

Hainsworth JD, Spigel DR, Barton J, Farley C, Schreeder M, Hon J, Greco FA.

Cancer. 2008 Aug 15;113(4):765-71. doi: 10.1002/cncr.23606.

12.

Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients.

Broyl A, Hose D, Lokhorst H, de Knegt Y, Peeters J, Jauch A, Bertsch U, Buijs A, Stevens-Kroef M, Beverloo HB, Vellenga E, Zweegman S, Kersten MJ, van der Holt B, el Jarari L, Mulligan G, Goldschmidt H, van Duin M, Sonneveld P.

Blood. 2010 Oct 7;116(14):2543-53. doi: 10.1182/blood-2009-12-261032. Epub 2010 Jun 23.

13.

Ectopic cyclin D1 overexpression increases chemosensitivity but not cell proliferation in multiple myeloma.

Kuroda Y, Sakai A, Tsuyama N, Katayama Y, Munemasa S, Asaoku H, Okikawa Y, Nakaju N, Mizuno M, Ogawa K, Nishisaka T, Matsui H, Tanaka H, Kimura A.

Int J Oncol. 2008 Dec;33(6):1201-13.

PMID:
19020753
14.

Bortezomib in combination with conventional chemotherapeutic agents for multiple myeloma compared with bortezomib alone.

Min CK, Lee MJ, Eom KS, Lee S, Lee JW, Min WS, Kim CC, Kim M, Lim J, Kim Y, Han K.

Jpn J Clin Oncol. 2007 Dec;37(12):961-8. Epub 2007 Dec 21.

PMID:
18156171
15.

Bortezomib in combination with dexamethasone and subsequent thalidomide for newly-diagnosed multiple myeloma: a Chinese experience.

Zheng W, Wei G, Ye X, He J, Li L, Wu W, Shi J, Zhang J, Huang W, Xie W, Luo Y, Xue X, Lin M, Huang H, Cai Z.

Leuk Res. 2009 Dec;33(12):1615-8. doi: 10.1016/j.leukres.2009.04.006.

PMID:
19773080
16.

Expression of c-Kit isoforms in multiple myeloma: differences in signaling and drug sensitivity.

Montero JC, López-Pérez R, San Miguel JF, Pandiella A.

Haematologica. 2008 Jun;93(6):851-9. doi: 10.3324/haematol.12171. Epub 2008 Apr 28.

17.

[Bortezomib in relapsed or refractory multiple myeloma: results in a cohort of 39 patients].

Cánovas Fernández A, Alonso Alonso JJ, Barreiro García JG, Aguirre Errasti C.

Rev Clin Esp. 2008 Apr;208(4):187-92. Spanish.

PMID:
18381003
18.

Proteasome inhibition and multiple myeloma.

Kanagasabaphy P, Morgan GJ, Davies FE.

Curr Opin Investig Drugs. 2007 Jun;8(6):447-51. Review.

PMID:
17621873
19.

Bortezomib in the front-line treatment of multiple myeloma.

Richardson PG, Mitsiades C, Schlossman R, Ghobrial I, Hideshima T, Munshi N, Anderson KC.

Expert Rev Anticancer Ther. 2008 Jul;8(7):1053-72. doi: 10.1586/14737140.8.7.1053. Review.

PMID:
18588451
20.

A striking response to bortezomib in a patient with pleural localization of multiple myeloma.

Mangiacavalli S, Varettoni M, Zappasodi P, Pica G, Lazzarino M, Corso A.

Leuk Res. 2009 Apr;33(4):577-8. doi: 10.1016/j.leukres.2008.08.027. Epub 2008 Oct 7. No abstract available.

PMID:
18842298

Supplemental Content

Support Center